Malignancy Clinical Trials in Hangzhou, Zhejiang
13 recruitingHangzhou, Zhejiang, China
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
Advanced Malignancy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.200 enrolled2 locationsNCT07123129
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Phase 1
A Study of GLB-001 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+3 more
Hangzhou GluBio Pharmaceutical Co., Ltd.108 enrolled14 locationsNCT06378437
Recruiting
Phase 1
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Hematologic MalignancyAML (Acute Myelogenous Leukemia)Refractory Acute Myeloid Leukemia+3 more
Hangzhou Weben Pharma Co., Ltd18 enrolled1 locationNCT07014449
Recruiting
Phase 1
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Advanced Solid TumorNon-small Cell Lung CancerHematologic Malignancy
Shenzhen TargetRx Co., Ltd.90 enrolled1 locationNCT06484816
Recruiting
Phase 1
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.111 enrolled8 locationsNCT06615193
Recruiting
Early Phase 1
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
CancerSolid TumorHematologic Malignancy
Westlake Therapeutics30 enrolled1 locationNCT05707325
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662
Recruiting
Phase 2
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Hematologic MalignancyStem Cell Transplant Complications
First Affiliated Hospital of Zhejiang University95 enrolled1 locationNCT04809181